Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kintor Pharmaceutical Limited has announced the approval of its tyrosinase inhibitor, KT-939, by the International Cosmetic Ingredient Nomenclature Committee, paving the way for its application in the booming whitening and freckle-removing cosmetics market. The compound has demonstrated superior efficacy and safety compared to existing alternatives, positioning it as a promising ingredient for high-end cosmetic products. This development could enhance Kintor’s competitive edge and market share in the cosmetics industry.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.